Summary
44.33
0.12
(0.27%)
07/17/2026
Sanofi (SNY)Key Facts
Performance
Historical returns1D
0.27%
1W
1.63%
1M
0.36%
3M
-3.66%
6M
-1.32%
1Y
-5.25%
5Y
3.78%
Snapshot
Key statisticsClose
44.33
Change
0.12
Change %
0.27%
Open
44.19
Day Range
43.89 – 44.85
Volume
1,876,687
Avg Vol (20d)
4,390,530
Rel Vol
0.43x
52W Range
40.89 - 50.66
vs 52W High
-12.49%
vs 52W Low
8.41%
Gap
-0.03
Market Cap
USD 123.49B
Beta
0.37
Dividend Yield
4.13%
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 2× | 0.00% |
| 1-Month | 6× | 0.00% |
| 3-Month | 0× | -4.09% |
| 6-Month | 5× | -6.40% |
| YTD | 3× | -6.40% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 10× | -11.92% |
| 2-Year | 21× | -19.02% |
| 3-Year | 23× | -19.02% |
| 5-Year | 31× | -19.02% |
| 10-Year | 81× | -19.02% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 43.63B
-1.5% YoY
Net Income
USD 4.94B
-10.1% YoY
EPS
6.40
+44.1% YoY
Gross Margin
70.1%
Operating Margin
32.7%
Net Margin
11.3%
EBITDA
USD 6.74B
Free Cash Flow
USD 8.99B
20.6% margin
ROE
6.9%
ROA
3.9%
Debt / Equity
0.31x
net debt USD 14.14B
Cash & Equiv.
USD 7.66B
Fundamental Ratings
MainA-
RecommendedBuy
DCFStrong Buy
ROENeutral
ROABuy
Debt/EquitySell
P/ESell
P/BBuy
Latest Earnings
- SNY reported last earnings on 2026-04-23.
- EPS of $1.1 vs $1.06 estimated — surprise $0.04.
- Revenue of $12,942M vs $12,677M estimated — surprise $265M.
News
All newsAqemia and Sanofi Expand Their Research Collaboration
PARIS & LONDON--(BUSINESS WIRE)-- #DrugDiscovery--Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The...
3 High-Yield Dividend Stocks to Buy and Hold
All three can be bought on the dip.
Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study
Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.
Press Release: Availability of the aide-mémoire for Q2 2026 results
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support...
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows
When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive dividend income.
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Is AbbVie a Buy After Its Purchase of Apogee?
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity
Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma peers despite solid results and strategic focus. Dupixent drives 40% of Sanofi's sales and 80% of Q1 incremental growth; management is pursuing lifecycle management to mitigate 2031 U.S. LOE risk....
Press Release: Sanofi Foundation opens new chapter centered on future generations
Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those living with serious diseases.
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.
Sanofi Multiple Sclerosis Drug Gets EU Approval
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet...
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi a ppoints Paulo Fontoura as Global Head of R&D Paris , June 22 , 2026. Sanofi today announced the appointment of Paulo F o ntoura , MD, PhD, FAAN, as Executi v e Vice President, Global Head of Research & Development Pharma, effective September 1, 2026.
Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-inferior efficacy and pharmacokinetics compared to Sarclisa IV Second global approval for Sarclisa...
Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First
Sanofi remains a compelling investment opportunity, driven by a robust pipeline and strong fundamentals. Sarclisa sales in Q1 of 2026 grew by 30.1% to $193.21 million; expansion with on-body injector [OBI] could make a push to compete in the MM space against Darzalex. Dupixent sales in Q1 of 2026...